%0 Journal Article
%K Humans
%K *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects
%K *Diabetes Mellitus, Type 2/drug therapy
%K Male
%K Female
%K *Glucagon-Like Peptide-1 Receptor/agonists
%K *Cardiovascular Diseases/prevention & control/epidemiology/mortality
%K Middle Aged
%K Aged
%K *Drug Therapy, Combination
%K Incidence
%K *Hypoglycemic Agents/therapeutic use/adverse effects
%K United Kingdom/epidemiology
%K Cohort Studies
%K Glucagon-like peptide-1 receptor agonists
%B Bmj
%D 2024
%G eng
%M 38663919
%P e078242
%R 10.1136/bmj-2023-078242
%T Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
%V 385
%2 PMC11043905 at https://www.icmje.org/disclosure-of-interest/ and declare: this study was funded by the Canadian Institutes of Health Research; LA received speaking and consulting fees from Pfizer and Roche for work unrelated to this project; SS attended scientific advisory committee meetings for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer, and Seqirus and received speaking fees from Boehringer-Ingelheim and Novartis; no other relationships or activities that could appear to have influenced the submitted work.
%7 2024/04/26
%@ 0959-8138 (Print)
0959-8138